Product
BI 655130
Aliases
BI 655130 (spesolimab), R - Low dose of BI 655130, Spesolimab, T1 - Low dose of BI 655130 (2 other aliases)
5 clinical trials
3 indications
Indication
HealthyIndication
DermatitisIndication
AtopicClinical trial
Safety, Tolerability, and Pharmacokinetics of Two Dose Strengths of a Single Subcutaneous Dose of BI 655130 and One Single Intravenous Dose of BI 655130 in Healthy Male and Female Subjects (Open-label, Parallel Group Design)Status: Completed, Estimated PCD: 2018-01-10
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 655130 (Double-blind, Partially Randomised Within Dose Groups, Placebo-controlled Parallel Group Design) and One Single Intravenous Dose of BI 655130 (Single-blind, Partially Randomised, Placebo-controlled) in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2017-08-01
Clinical trial
Single-blind, Partially Randomised, Placebo-controlled Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses of BI 655130 in Healthy Male VolunteersStatus: Completed, Estimated PCD: 2016-05-27
Clinical trial
Relative Bioavailability, Safety, and Tolerability Following Subcutaneous Injection of Different Doses of BI 655130 and Different Injection Sites in Healthy Male and Female Subjects (a Single Dose, Mono-centric, Open-label Study in Matched-group Design).Status: Completed, Estimated PCD: 2019-06-03
Clinical trial
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2020-01-17